NCT07592013Enrolling by invitation
Effect of Ancestry Supplementation in Subjects With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Effect of Ancestry Supplementation on the Abundance of Beneficial Bacterial Genera in the Gut Microbiota in Subjects With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Source: ClinicalTrials.gov · Last updated 18 May 2026
Brief summary (registry, in English)
The goal of this clinical trial is to evaluate the effect of Ancestry, a supplement made from Mexican-origin foods (nopal, cacao, and cricket) in adults with Metabolic dysfunction-associated steatotic liver disease (MASLD). The main questions it aims to answer are: * Does the supplementation with Ancestry improve the hepatic steatosis grade in participants with MASLD? * Does the supplementation improve biochemical and anthropometric parameters in participants with MASLD? * Does the supplementation enrich the abundance of beneficial bacteria in the gut microbiota of participants? Researchers will compare the supplement group to a placebo group to see if the supplement is effective. Participants will: * Take the supplement or a placebo every day for 3 months. * Receive nutritional guidance from a trained dietitian to control dietary intake. * Attend follow-up clinic visits every month for monitoring and checkups.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 30 Apr 2026
- Start date
- Feb 2025
- Primary completion date
- Oct 2026
- Lead sponsor
- University of Guadalajara
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT07592013
What you commit to
- Study type: Interventional
- Planned participants: 60
- From Feb 2025 to the primary completion date, Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current or prior 6 weeks consumption of probiotic formulations
- Current or prior 2 months consumption of antibiotics or antiparasitic drugs before the start of the study
- Frequent consumption (greater than or equal to twice a week) of anti-inflammatory drugs, analgesics, or medications that alter normal intestinal function (e.g., laxatives, enemas, antidiarrheal agents, etc.)
- Previous malabsorptive bariatric surgery (gastric bypass, sleeve gastrectomy), restrictive bariatric surgery (adjustable gastric band), or cosmetic surgical procedures (liposuction, lipo-sculpture, abdominoplasty, etc.) in the last 2 years
Other illness
- Severe gastrointestinal diseases (e.g., chronic constipation, Crohn's disease, celiac disease, ulcerative colitis, irritable bowel syndrome, diverticulosis, etc.), autoimmune diseases, and malignant neoplasms
- Allergy or intolerance to cacao, nopal, or crickets
Other
- Current consumption of dietary supplements (omega-3 fatty acids, thermogenics, protein, teas, etc.)
- Pregnant women, women planning pregnancy, or breastfeeding women
- Weight loss greater than three kilograms in the last month
- Tobacco consumption
Who the study is looking for
- Mexican mestizo adults of both sexes between 18 to 60 years old
- Diagnosis of MASLD according to the criteria established by the American Association for the Study of Liver Diseases
- Controlled Attenuation Parameter (CAP) score \>248 dB/m, liver stiffness \<14 kPa according to FibroScan Expert 630 (Echosens, Paris, France)
- Obesity diagnosed by body fat percentage
- Bristol stool scale type 3-4
- Physical inactivity according to the International Physical Activity Questionnaire (IPAQ)
- Alcohol consumption \<20 grams/day for women and \<30 grams/day for men
- Signed informed consent
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institute of Molecular Biology in Medicine and Gene Therapy Coordinator of this site? Confirm its status | Guadalajara | Mexico | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.